ArticleBiomolecules2026
Comparative Analysis of Reported Gene Targets and Binding Regions of Glu-CTC tRNA Fragments Across Human Diseases.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent detection of overlapping tRNA-derived fragments (tRFs) across diverse disease conditions supports the emerging view that tRFs may act as regulatory molecules rather than random degradation products. While cases of identical tRFs have been described, their comparative analyses are lacking. tRF-Glu-CTC is one such fragment, repeatedly detected in various pathological conditions. We performed a comparative analysis of tRF-Glu-CTC isoforms, their targets and binding regions reported in 18 disease-associated studies. An 18-nucleotide sequence, TCCCTGGTGGTCTAGTGG, was identified in most (14 out of 18) of these studies despite differences in tRF naming, length and disease context. Several reported tRF targets showed consistent binding regions, with reverse complementarity to the tRF sequence. Comparison with databases of tRF targets, tatDB and tRFTar, identified matching target entries and sequence overlaps, often involving common regions rather than full-length matches. Exploratory analysis of target homologs further illustrated that related genes might share candidate target sites. Our findings indicate that tRF-Glu-CTC represents a recurrent candidate regulatory fragment potentially relevant in a broad range of human diseases. Its structural stability, extracellular vesicle association, detection in multiple species and a core sequence shared between related isoforms support further investigation of its biological and translational relevance. Our work illustrates how tRF target databases can be leveraged to advance smaller-scale tRF studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.